Charles joined the Board of IXICO in July 2013 having previously been an adviser on corporate strategy to the Board since 2011. He is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors. He is currently Non-Executive Chairman of Realm Therapeutics plc (formerly PuriCore plc), Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health’s Invention for Innovation Funding Panel. He has also served as Non-Executive Director of Stanmore Implants and Aircraft Medical. He was previously Chief Executive of MDY Healthcare plc, a strategic healthcare investor and prior to that, Head of Healthcare Corporate Finance at both Numis Securities and Nomura International. Charles has an MA in History from Cambridge University.
Chief Executive Officer
Giulio joined IXICO as Chief Executive Office in February 2017. He has over 30 years of experience in the life science and diagnostic sectors and has led business operations ranging from £4M to £125M of revenues. He was previously Managing Director of the Genomics division of the LGC group, the private equity owned international life science measurement and testing company. In addition to trebling revenues in under four years and completing three acquisitions in eighteen months, Giulio was a member of the executive leadership team responsible for the successful sale of LGC group to the leading private equity firm, KKR. Guilio also held a variety of leadership positions across both the Life Science and Anatomical Pathology Divisions at ThermoFisher Scientific. These included Managing Director, Vice President Commercial Operations EMEA and APAC, with his final post being the Global Vice President and General Manager of the 1,200 employee Anatomical Pathology organisation. His first eighteen years were spent in business development and divisional leadership roles with Dupont and Anachem. Giulio holds a BSc from Cardiff University and an MBA (distinction) from Warwick University.
Derek is a founder and former CEO of IXICO. He was responsible for setting and delivering the business strategy which has included leading the company to profitability in 2012 and the subsequent admission to AIM in October 2013. Derek has worked in medical imaging science for over 25 years and has authored more than 80 journal papers in this field. He is a member of the MRI Core of the Alzheimers disease Neuroimaging Initiative ADNI in the US, has served on the scientific advisory board for several pharmaceutical companies and is involved in the Critical Path Institute’s Coalition Against Major Diseases CAMD biomarker qualification initiatives. Derek has a PhD in medical image analysis at the Medical School of Guy’s & St Thomas’ Hospitals, University of London, an MSc in Medical Physics at the University of Surrey and a BSc degree in Physics from Imperial College. He undertook business training at London Business School as part of the CSEL programme.
Chief Financial Officer and Company Secretary
Susan joined IXICO as Chief Financial Officer in October 2014. She was previously Group Chief Financial Officer and a Director of Novacyt SA, a European diagnostic company listed on the French Alternext exchange. Prior to that, she was Chief Financial Officer and a Director of Lab21 Group Limited which was acquired by Novacyt in June 2014. Susan also held executive positions at BioWisdom Limited where she was Chief Financial Officer until its acquisition by Instem plc and Finance Director at RiboTargets Limited until its acquisition by Vernalis plc. She has held senior financial management roles at other life science companies including Lonza Biologics, Celltech Group and Monsanto, gaining significant experience in growing businesses and corporate transactions.
John is a chartered accountant with more than 15 years’ experience as a Chief Financial Officer with venture capital backed and listed companies. He is a partner in Bradshaw Daniel, which provides Chief Financial Officer services to small and medium sized companies throughout the UK and Europe. He is the Chief Financial Officer of Syncona Partners LLP, an independent subsidiary of the Wellcome Trust founded in 2012 to invest in healthcare. He was previously Chief Financial Officer of Gyrus Group PLC, which he joined prior to listing it on the London Stock Exchange, following 11 years at Arthur Andersen in Cambridge and Turin where he qualified as a chartered accountant. John has a law degree from the University of Liverpool. John chairs the Audit Committee.
Non-Executive Director and Senior Independent Director
Tim has more than 25 years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. He has broad experience in drug development, product licensing, mergers, acquisitions and fundraisings. Previous positions include Chief Executive Officer at Phytopharm PLC and SerentisLimited , and Executive Vice President at Vectura PLC. Tim led product development at Arakis Ltd. and US-based Sequus Inc. following a period of time at Pfizer. His CRO experience was gained at ICON, one the world’s largest CROs, where he led European operations. Tim was also a Non-Executive Director at Clinical Force Limited, a clinical trial software company, until its successful trade sale in 2011. Tim chairs the Remuneration Committee.
Mark became a Non-Executive Director of IXICO in September 2016. He is currently Head of IP Group’s Healthcare division which at the end of December 2015 had shareholdings in 31 companies valued at over £275 million. Mark also represents IP Group on the boards of a number of its portfolio companies, both quoted and private; notably hVIVO plc, Genomics plc, Cronin Group plc and Crysalin Limited. Mark has been at IP Group since 2008 and has extensive experience in building world-changing healthcare businesses as well as in managing transactions including portfolio company IPOs, financings and M&A. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was managing director. Mark spent 8 years at Exelgen (formerly known as Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.